KRRO-111's best-in-class preclinical profile adds pipeline optionality to the OPERA platform thesis and may attract partnership interest. Monitor KRRO-121 regulatory filing in H2 2026 as the next major catalyst; also watch for third liver asset nomination and eventual Phase 1 data readouts from both programs.
Price Chart
Executive Summary
Korro Bio selected KRRO-111 as a development candidate for Alpha-1 Antitrypsin Deficiency (AATD), a genetic disease affecting ~3.4 million people worldwide. Preclinical data showed >90% SERPINA1 RNA editing and ~90% functional M-AAT protein in a mouse model, plus near-elimination of pathogenic Z-protein production. The company also reiterated its cash runway into H2 2028 ($157.1M as of March 31, 2026), a planned regulatory filing for KRRO-121 in H2 2026, and a third GalNAc-liver asset development candidate expected in H2 2026.
Key Facts
- KRRO-111 selected as development candidate for AATD; demonstrated >90% SERPINA1 RNA editing and ~90% M-AAT protein in vivo
- Repeat-dose study (3 mg/kg Q2W) showed near-elimination of active Z-protein (~95% reduction vs vehicle) and progressive clearance of pre-existing aggregates (~69% reduction at day 28)
- Cash, cash equivalents, and marketable securities of $157.1M as of March 31, 2026; cash runway into H2 2028
- Regulatory filing for KRRO-121 (urea cycle disorders) anticipated in H2 2026
- Third GalNAc-conjugated liver asset development candidate expected in H2 2026
- Potential for partnership across pipeline noted in corporate presentation
Financial Impact
No financial terms disclosed; $157.1M cash runway into H2 2028 supports both KRRO-111 and KRRO-121 clinical programs
Risk Factors
- All data are preclinical; clinical translation is not guaranteed
- AATD is a competitive space with existing augmentation therapy and other RNA-based approaches in development
- Korro is pre-revenue with no approved products; reliance on capital markets for funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-229610 |
| Document: krro-ex99_1.htm | 0001193125-26-229610 |
| Document: krro-ex99_2.htm | 0001193125-26-229610 |
| Document: 0001193125-26-229610-index-headers.html | 0001193125-26-229610 |
| Document: 0001193125-26-229610-index.html | 0001193125-26-229610 |
| Document: 0001193125-26-229610.txt | 0001193125-26-229610 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $12.73 | awaiting T+1 | — | $13.30 (+4.48%) |
Oct 26, 2026 1d ago | Insider Buy | $12.46 | awaiting T+1 | — | $13.30 (+6.74%) |
Oct 22, 2026 5d ago | 8-K | $12.05 $11.98 | ▼ −0.58% | ▼ −0.06% | $13.30 (+10.37%) |
Oct 16, 2026 11d ago | Press Release | $8.91 $9.44 | ▲ +5.95% | ▲ +5.61% | $13.30 (+49.27%) |
Oct 5, 2026 22d ago | 8-K | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $13.30 (+36.27%) |
Oct 5, 2026 22d ago | Press Release | $9.76 $10.49 | ▲ +7.48% | ▲ +7.72% | $13.30 (+36.27%) |
Sep 15, 2026 6w ago | Insider Cluster | $13.83 $11.80 | ▼ −14.68% | ▼ −15.81% | $13.30 (−3.83%) |
Aug 13, 2026 10w ago | Insider Cluster | $13.29 $13.28 | ▼ −0.08% | ▲ +0.12% | $13.30 (+0.08%) |
Aug 6, 2026 11w ago | 8-K | $12.12 $13.25 | ▲ +9.32% | ▲ +8.71% | $13.30 (+9.74%) |
Jul 9, 2026 15w ago | Institutional Cluster | $14.30 $14.56 | ▲ +1.82% | ▲ +1.39% | $13.30 (−6.99%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers